One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib
Tanya T. Kwan, PhD; Amit M. Oza, MD; Anna V. Tinker, MD; et al.
Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer
Alexander Melamed, MD, MPH; J. Alejandro Rauh-Hain, MD, MPH; Allison A. Gockley, MD; et al.
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, ERBB2-Negative Advanced Breast CancerA Randomized Clinical Trial
Antonio Llombart-Cussac, MD; José Manuel Pérez-GarcÃa, MD; Meritxell Bellet, MD; et al.
Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data SetAn International Agency for Research on Cancer TP53 Database Analysis
Christian P. Kratz, MD; Claire Freycon, MD; Kara N. Maxwell, MD, PhD; et al.
Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes
Catherine Goudie, MD; Leora Witkowski, PhD; Noelle Cullinan, MD; et al.
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma
Laure Hirsch, MD; Nieves Martinez Chanza, MD, PhD; Subrina Farah, MS; et al.
Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non–Small Cell Lung Cancer in the US
Apar Kishor Ganti, MD; Alyssa B. Klein, MPH; Ion Cotarla, MD, PhD; et al.
Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening
Iakovos Toumazis, PhD; Koen de Nijs, MSc; Pianpian Cao, MPH; et al.
Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers
Ravi B. Parikh, MD, MPP; Eun Jeong Min, PhD; E. Paul Wileyto, PhD; et al.
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung CancerA Phase 1/2 Open-label Nonrandomized Clinical Trial
Caicun Zhou, PhD, MD; Suresh S. Ramalingam, MD; Tae Min Kim, MD, PhD; et al.
Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy—A Rare Event
Andrea V. Barrio, MD; Giacomo Montagna, MD, MPH; Anita Mamtani, MD; et al.
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With CancerA Multicenter International Cohort Study
Caroline A. Nebhan, MD, PhD; Alessio Cortellini, MD; Weijie Ma, MD; et al.
Occurrence of Pancytopenia Among Patients With Cancer Treated With Poly(Adenosine Diphosphate–Ribose) Polymerase InhibitorsA Pharmacoepidemiologic Study
Pierre-Marie Morice, PharmD, PhD; Basile Chrétien, PharmD, MSc; Angélique Da Silva, MD; et al.
Association of Smoking Initiation and Cessation Across the Life Course and Cancer MortalityProspective Study of 410 000 US Adults
Blake Thomson, DPhil; Jonathan Emberson, PhD; Ben Lacey, MBChB, DPhil; et al.
Compliance With Price Transparency Rules at US National Cancer Institute–Designated Cancer Centers
Fumiko Chino, MD; Jordan Johnson, BSRT, MSHA; Haley Moss, MD
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug ConjugatesA Review
Paolo Tarantino, MD; Shanu Modi, MD; Sara M. Tolaney, MD, MPH; et al.
COVID-19 and CancerA Review of the Registry-Based Pandemic Response
Aakash Desai, MD, MPH; Turab J. Mohammed, MD; Narjust Duma, MD; et al.
Painful Eruptions in a Patient With Cholangiocarcinoma Treated With Fibroblast Growth Factor Receptor Inhibitor
Natasha S. Wylie, DNP, APRN; Olayemi Sokumbi, MD; Jason S. Starr, DO
Has the Current Oncology Value Paradigm Forgotten Patients’ Time?Too Little of a Good Thing
Adam Fundytus, MD; Vinay Prasad, MD, MPH; Christopher M. Booth, MD
Adjuvant Chemotherapy for Stage I Pancreatic Ductal Adenocarcinoma—Is It Based on Evidence or Clinical Wisdom?
Lorenzo Gervaso, MD; Florian Lordick, MD, PhD; Nicola Fazio, MD, PhD
A Coordinated Policy Approach to Address Medical Financial Toxicity
Cathy J. Bradley, PhD; K. Robin Yabroff, PhD; Ya-Chen Tina Shih, PhD
Poly(ADP-Ribose) Polymerase Inhibitors and Myeloid Neoplasm Risk—Clues to a Mechanistic Connection?
Christine Walsh, MD, MS; Ilana Cass, MD
The Long, Slow Road to Lung Cancer Cure
James L. Mulshine, MD; Bruce Pyenson, FSA, MAAA
Immunotherapy Adverse Effects
Timothy J. Brown, MD; Ronac Mamtani, MD, MSCE; Erin M. Bange, MD
